What Are the Side Effects of GLP-1 Drugs? A Research-Backed Guide

GLP-1 receptor agonists — the class of drugs that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become among the most prescribed medications in the world. Prescriptions increased by 364% between 2019 and 2024. They work. But the clinical picture on side effects is more complex, and more concerning in certain areas, than mainstream coverage suggests. In this article

1. What are GLP-1 drugs?
2. Gastrointestinal side effects
3. Muscle and lean mass loss
4. Bone density reduction
5. Pancreatitis and pancreatic risk
6. Skin and hair changes
7. Mental health effects
8. Eye health
9. Weight regain after stopping
10. Healthy alternatives to weight loss drugs
11. The bottom line

What Are GLP-1 Drugs?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a hormone your gut naturally produces after eating. That hormone signals the pancreas to release insulin, slows gastric emptying, and — crucially for weight loss use — signals the brain’s appetite centres to reduce hunger. Originally developed as type 2 diabetes medications in 2005, they are now widely prescribed for weight management. The major drugs in this class include:

• Semaglutide — sold as Ozempic (diabetes) and Wegovy (weight loss)
• Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight loss); targets both GLP-1 and GIP receptors
• Liraglutide — sold as Victoza (diabetes) and Saxenda (weight loss)
• Dulaglutide — sold as Trulicity
• Exenatide — sold as Byetta and Bydureon

Their weight loss efficacy is well-established. The landmark STEP 1 trial showed semaglutide produced a mean weight loss of 14.9% at 68 weeks. The SURMOUNT-1 trial showed tirzepatide at 15mg produced weight loss of up to 20.9% at 72 weeks — figures previously unachievable outside of bariatric surgery. But what does the research actually say about the downsides?

Gastrointestinal Side Effects: The Most Common Complaint

The most consistently documented side effects of GLP-1 drugs are gastrointestinal. A 2023 systematic review and network meta-analysis published in Frontiers in Endocrinology, which enrolled 64 randomised controlled trials covering 16,783 patients, found that nausea, vomiting, diarrhoea, and constipation were the primary reasons patients discontinued treatment. The key findings from this research:

• Nausea affects 15–44% of patients depending on the drug and dose, with semaglutide showing higher rates than dulaglutide
• Vomiting affects 5–24% of patients, again dose-dependent
• Diarrhoea affects roughly 8–30% of users
• Constipation — particularly with tirzepatide — affects up to 11% of users

The analysis found that the risk of intolerable gastrointestinal adverse reactions was higher with liraglutide and semaglutide than with dulaglutide, and that higher doses of the same drug consistently produced more gastrointestinal side effects. These effects tend to be worst in the first few weeks of treatment or after dose increases, and improve over time for many patients — but for a significant subset, they are severe enough to cause discontinuation.

Muscle and Lean Mass Loss: A Significant Concern

One of the most important and underreported findings in GLP-1 research is the extent to which weight loss from these drugs is not purely fat loss. Muscle and lean mass loss is a consistent finding across the major trials. Losing significant lean mass has real-world consequences: it reduces resting metabolic rate (making future weight maintenance harder), reduces strength and functional capacity, and increases the risk of the very cardiometabolic complications these drugs are meant to treat. The research on mitigation is encouraging, however. A clinical trial found that the main drivers of lean mass loss were inactivity and low protein intake rather than the medication itself — and participants who kept exercising, especially strength training, lost far less muscle than those who were inactive. This means the muscle loss risk is substantially modifiable. Combining GLP-1 therapy with a consistent strength training programme and adequate protein intake significantly reduces lean mass loss — though this is rarely communicated to patients at the point of prescription.

Bone Density Reduction: Emerging Evidence

The effects of GLP-1 drugs on skeletal health have received less public attention than gastrointestinal side effects, but the data warrants serious consideration — particularly for older patients and postmenopausal women. Postmenopausal women represent the highest-risk group. After menopause, the decline in oestrogen already drives average bone density losses of 1–2% per year, and this compounds with drug-related losses. Bone changes tend to slow and stabilise once body weight stabilises, and some studies suggest the drug effect on bone turnover is relatively neutral — with reductions driven primarily by rapid weight loss and reduced mechanical loading. For patients with osteopenia, osteoporosis, or elevated fracture risk, GLP-1 therapy without a bone protection plan is incomplete care.

Pancreatitis and Pancreatic Risk

Acute pancreatitis and its connection to GLP-1 receptor agonists has been a persistent area of investigation since the drugs’ introduction. A 2024 updated meta-analysis published in Endocrinología, Diabetes y Nutrición examined multiple semaglutide regimens and found a statistically significant association with acute pancreatitis incidence. The absolute risk remains low, and causality is not definitively established across all studies — obesity itself is an independent risk factor for pancreatitis, making isolation of the drug effect difficult. Current prescribing guidelines advise caution in patients with a history of pancreatitis. Patients should know the warning signs: severe, persistent abdominal pain radiating to the back. On pancreatic cancer, a 2025 study in the Journal of the National Cancer Institute used real-world data to examine GLP-1 receptor agonist use and pancreatic cancer risk. The literature remains mixed and no definitive causal link has been established — but this is an area of active monitoring by regulators.

Skin and Hair Changes

Dermatological side effects are among the more recently documented and frequently underreported effects of GLP-1 drugs. A 2025 systematic review published on NCBI PubMed, covering 51 studies from 2014–2025, found that adverse dermatological effects included hypersensitivity reactions, injection-site reactions, pruritus (itching), urticaria (hives), angioedema, and immune-mediated conditions including bullous pemphigoid — a serious blistering skin disease. Hair loss (telogen effluvium) is increasingly reported by users, particularly during the rapid weight loss phase. This is typically temporary and related to the physiological stress of rapid weight change rather than a direct drug effect — but it is a significant quality-of-life concern for many patients.

Mental Health Effects: A Contested and Evolving Area

The mental health effects of GLP-1 drugs represent one of the most actively debated areas in current pharmacological research. The picture is mixed and the evidence base is still developing. On the positive side, some research has shown reductions in food-related anxiety and improved mood from weight loss outcomes. GLP-1 receptors are expressed throughout the brain, and early research suggests possible benefits for conditions including addiction, Alzheimer’s disease, and depression in some contexts. However, concerning signals have emerged: A case report presented at the 2024 American Psychiatric Association annual meeting described a 42-year-old woman who developed protracted nihilistic delusions and an attempted self-strangulation just three weeks after beginning semaglutide. While a single case report cannot establish causality, it highlights the need for psychiatric monitoring — particularly in patients with pre-existing mental health conditions. Both the European Medicines Agency and the FDA have stated they are actively monitoring incoming reports related to suicidal ideation across this drug class.

Eye Health and Vision Changes

Some emerging risks include possible impacts on eye health. Of particular concern is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) — a form of sudden vision loss caused by reduced blood flow to the optic nerve. The FDA updated the Ozempic label in 2024 to include a warning about this rare but serious risk. Patients with pre-existing eye conditions, diabetes-related retinopathy, or a history of optic nerve problems are considered at elevated risk.

Weight Regain After Stopping

Sustained use is often necessary to prevent significant weight regain — meaning the drug must be taken indefinitely for most patients to maintain results. The STEP 1 extension trial, which followed patients after they discontinued semaglutide, showed that by one year off the drug, two-thirds of the weight lost had been regained. This is not unique to GLP-1 drugs — it mirrors what happens after stopping most pharmacological obesity interventions — but it has significant implications for long-term health planning and cost-benefit analysis for any given patient. This dependency dynamic underscores why building sustainable lifestyle habits during GLP-1 treatment is so clinically important — not as an alternative, but as a parallel investment.

Healthy Alternatives to Weight Loss Drugs

GLP-1 drugs are clinically appropriate for some patients — particularly those with severe obesity, type 2 diabetes, or high cardiovascular risk. But for many people considering them primarily for weight loss, the side effect profile and long-term dependency raise a legitimate question: what do evidence-based, drug-free alternatives actually look like? The same outcomes GLP-1 drugs target — reduced appetite, improved insulin sensitivity, weight loss, better cardiovascular markers — are achievable through lifestyle interventions. They require more consistent effort, but come without the gastrointestinal, musculoskeletal, and psychiatric risks described above.

1. Resistance Training

Strength training is one of the most evidence-backed interventions for body composition and metabolic health. It preserves lean mass during a caloric deficit — the exact problem GLP-1 drugs exacerbate — increases resting metabolic rate, improves insulin sensitivity, and drives long-term fat loss in ways that cardio alone does not. The research on GLP-1 users consistently shows that patients who combine therapy with structured strength training lose significantly less muscle than those who do not. Whether or not you choose pharmacological support, a strength training programme is one of the most powerful tools available. See our full workout routines library for structured programming from beginner to advanced.

2. High-Protein Diet

Protein is the single most important dietary lever for weight loss and body composition. High-protein diets reliably reduce appetite (partly through stimulating natural GLP-1 secretion), preserve lean mass in a caloric deficit, and produce greater fat loss than equivalent carbohydrate or fat intake at the same calories. The research-supported target for weight loss is 0.7–1g of protein per pound of bodyweight daily. For most people on a typical Western diet, this is meaningfully higher than current intake — and increasing it alone can produce significant body composition changes. Getting adequate protein from whole food sources is the priority. For those who struggle to hit targets through food alone, supplementation is one of the most well-studied and effective tools available. Our full guide to the best protein powders covers whey, casein, and plant-based options with independent quality rankings — including dedicated guides to whey protein and vegan protein.

3. HIIT Training

High-intensity interval training is among the most time-efficient methods for improving cardiovascular health and supporting fat loss. Research shows HIIT improves insulin sensitivity, reduces visceral fat, and produces cardiovascular adaptations comparable to much longer steady-state cardio in a fraction of the time. Three 20-minute sessions per week has been shown to produce meaningful improvements in metabolic health markers. See our HIIT training guides for structured programme options.

4. Sleep and Stress Management

These are consistently the most neglected and most impactful lifestyle variables in weight management. Poor sleep directly elevates ghrelin (the hunger hormone) and suppresses leptin (the satiety hormone) — creating a biochemical environment that makes caloric restraint extremely difficult. Chronic stress elevates cortisol, which drives visceral fat accumulation independently of caloric intake. Adults require 7–9 hours of quality sleep per night for optimal hormonal function.

5. Evidence-Based Supplements

No supplement replicates the appetite suppression of GLP-1 drugs, but several have a genuine evidence base for supporting weight loss and metabolic health alongside training and nutrition: Our complete supplements guide covers every major category with independent reviews.

The Bottom Line

GLP-1 drugs are genuine medical innovations with strong efficacy data. For people with significant obesity, type 2 diabetes, or elevated cardiovascular risk, the benefits in many cases outweigh the risks. But they are not a clean solution. The safety profile of GLP-1s is still evolving — with emerging risks across eye health, mental health, bone density, and muscle mass that deserve honest discussion at the point of prescription. The long-term dependency required to maintain results is also a significant practical and economic consideration. For people without a clinical obesity diagnosis who are considering GLP-1 drugs primarily for cosmetic weight loss, the evidence strongly supports trying structured lifestyle interventions first: consistent training, adequate protein, quality sleep, and a sustainable caloric deficit produce meaningful body composition changes for the vast majority of people who apply them consistently — without the side effects, the cost, or the long-term dependency.

---

References

1. Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity (STEP 1).” New England Journal of Medicine, 2021;384:989–1002.
2. Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).” New England Journal of Medicine, 2022;387:205–216.
3. Zhang Z, et al. “GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.” Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1149328.
4. Hansen SH, et al. “Effects of semaglutide on bone mineral density and microarchitecture.” eClinicalMedicine, 2024 (Phase 2 RCT).
5. Look M, et al. “Body composition outcomes with tirzepatide: SURMOUNT-1 DXA substudy.” Diabetes, Obesity and Metabolism, 2025.
6. Kornelius E, et al. “GLP-1 receptor agonist use and psychiatric outcomes in patients with obesity.” Scientific Reports, Vol. 14, Article 24433, 2024.
7. Sharafshah A, et al. “GLP-1 receptor agonists and suicidal ideation in low-dopamine phenotypes.” Current Neuropharmacology, 2025;23(8).
8. Salazar CE, et al. “Rare cutaneous adverse reactions associated with GLP-1 agonists.” Archives of Dermatological Research, 2024;316:248.
9. Wang L, et al. “GLP-1 receptor agonists and pancreatic cancer risk.” Journal of the National Cancer Institute, 2025;117:476–485.
10. Levels Health. “What the latest research says about GLP-1s in 2025.” December 2025.

This article is for informational purposes only. Consult a healthcare professional before starting, stopping, or changing any medication.